BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Weekly average mortgage rates jumped to their highest levels since September 2025 amid the spring homebuying season. The U.S. 30-year fixed mortgage rate averaged 6.51% during the week ending on May ...
Ashley is a former lead editor of mortgages and loans at Forbes Advisor. She graduated from Utah Tech University with a bachelor’s in English with an emphasis in creative writing. She began her career ...
Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results